Calendar

An AMCP Webinar.

Artificial intelligence is beginning to reshape how medicine is practiced and more specifically how medications are prescribed, reviewed, and monitored - and Utah is one of the first states to pilot an AI-enabled prescribing model at scale. In this webinar, Dr. Byron Crowe of Doctronic will provide a high-level overview of the Utah AI prescribing pilot, explaining how the model works in practice and what it could mean for the future of medication management.

Designed for managed care pharmacists, the session will explore how AI is being used to support clinical decision-making at the point of prescribing, including how patient data, clinical guidelines, and safety checks are integrated into the workflow. Dr. Crowe will also discuss the governance, oversight, and regulatory considerations that shaped the pilot, as well as early lessons learned around safety, quality, and provider adoption.

The webinar will conclude with a forward-looking discussion on where AI-enabled prescribing is headed - implications for utilization management, formulary strategy, prior authorization, and the evolving role of pharmacists in an AI-supported care model.

An AMCP Webinar, presented by FormularyDecisions.

Managed care organizations and biopharmaceutical companies today are reimagining how to deliver sustained value and protect future innovation amid significant health policy changes. Key areas that will be covered in this upcoming AMCP webinar will include:

• Mapping the latest policy updates - ranging from manufacturer negotiations on drug pricing to government directives aimed at lowering health insurance costs.
• Forecasting potential future impacts for stakeholders in managed care pharmacy and the biopharmaceutical industry to empower informed decision-making and enhance patient support.
• Sharing real-world insights on how organizations are adapting to current and forecasted policy changes.

An AMCP Webinar, presented by FormularyDecisions.

The anti-obesity medication market is undergoing rapid transformation, driven by innovative therapies, regulatory shifts, and evolving payer strategies. In response, managed care organizations and biopharma companies are navigating uncertainties as traditional coverage pathways are redefined. To navigate this dynamic environment, stakeholders must stay informed about the therapeutic landscape, emerging regulatory developments, and payer perspectives that will impact coverage and reimbursement.

This AMCP webinar will provide actionable insights into the current landscape for anti-obesity medications, including key market trends such as direct-to-consumer models. Attendees will have the opportunity to engage directly with Cencora’s topic experts during the live session, gaining real-time insights into the evolving market and implications for access.

An AMCP Market Insights Webinar.

This webinar distills critical highlights to empower US managed care pharmacists. We’ll dive deep into real-world barriers beyond the clinic, exploring how SDOH, coverage gaps, care fragmentation, and side effect management influence treatment success. Gain evidence-based strategies and payer-centric tools to bridge these gaps, foster equitable access, and deliver measurable value in a competitive market.

Attendees will emerge equipped with forward-thinking insights to transform AD care delivery, from rethinking prior authorizations to leveraging real-world data for smarter decision-making.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Otsuka Pharmaceutical Development & Commercialization, Inc.

ADHD is a complex neurodevelopmental disorder encompassing broad symptoms. Current pharmacologic treatments primarily address core symptoms with limited data on their impact on associated features. Evidence underscores the potential importance of three monoamines in ADHD presentation: DA, NE, and 5-HT.

This session covers efficacy and safety of a potential first-in-class NDSRI for ADHD treatment in children, adolescents, and adults. This agent is investigational and not FDA-approved.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Takeda Oncology.

AMCP and Takeda Oncology are pleased to invite you to a PIE webinar on rusfertide, an investigational, first‑in‑class hepcidin mimetic being studied for the treatment of polycythemia vera (PV)—a chronic blood disorder characterized by the overproduction of red blood cells. We’ll review the unmet need, key clinical data, and anticipated product profile, followed by a brief Q&A. We look forward to your participation.

This webinar is offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.